Medrx Co

Medrx Co ROCE

The Return on Capital Employed (ROCE) of Medrx Co (4586.T) as of Nov 19, 2026 is -45.97 %. In the previous year, Return on Capital Employed (ROCE) was -36.92 % — a change of 24.51% (lower).

ROCE

-45.97 %

YoY

24.51%

Last updated:

In 2025, Medrx Co's return on capital employed (ROCE) was -45.97 %, a 24.51% increase from the -36.92 % ROCE in the previous year.

The Medrx Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-59.77 JPY
Jan 1, 2019
-84.75 JPY
Jan 1, 2020
-52.64 JPY
Jan 1, 2021
-54.27 JPY
Jan 1, 2022
-91.32 JPY
Jan 1, 2023
-48.51 JPY
Jan 1, 2024
-36.92 JPY
Jan 1, 2025
-45.97 JPY
The Medrx Co ROCE history
YEARROCEYoY
-45.97 %+24.51%
-36.92 %-23.88%
-48.51 %-46.88%
-91.32 %+68.27%
-54.27 %+3.10%
-52.64 %-37.89%
-84.75 %+41.81%
-59.77 %+19.45%
-50.03 %-6.60%
-53.57 %+48.53%
-36.07 %+26.34%
-28.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Medrx Co's Return on Capital Employed (ROCE)

Medrx Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Medrx Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Medrx Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Medrx Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Medrx Co stock

Return on Capital Employed (ROCE) of Medrx Co is -45.97 % in 2025.

Return on Capital Employed (ROCE) of Medrx Co changed from -36.92 % to -45.97 %, representing a 24.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medrx Co

All Key Metrics — Medrx Co